Fennec Pharmaceuticals Inc. has appointed Jodi Cook to its board of directors the company announced in a statement Tuesday.

Cook is currently the head of gene therapy for PTC Therapeutics Inc., a global biopharmaceutical company. Before beginning her work at PTC, she helped found Agilis Biotherapeutics, a clinical-stage company focused on gene therapies, where she also served as chief operating officer.

“On behalf of the board of directors, we welcome the addition of Jodi Cook,” said Khalid Islam, Fennec’s chairman, in a press release. “She brings extensive scientific, clinical and executive business experience to the Company. Her background and track record of success will enhance our team as we further advance the commercialization and development strategy of PEDMARK.”

PEDMARK is a therapy intended to help children with hearing loss as a result of platinum-based chemotherapy. There is currently no preventative measure for this type of hearing loss. Fennec aims to complete its NDA submission for the treatment in early 2020 with a potential commercial launch of PEDMARK in the second half of 2020.

“I am delighted to be joining Fennec’s board of directors at this key point of development for PEDMARK,” said Cook in the press release. “Cisplatin induced hearing loss is a significant unmet medical need, a solution to which has evaded medicine for decades.”

Fennec’s stock was trading at $4.85 per share this morning, down four cents.